Japan’s GSK KK To Increase Relenza Supply By Two-Thirds
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline's Japan subsidiary said it would increase its supply of a substitute flu drug by two-thirds to have 5 million packs on hand. The action was taken after it was discovered the major drug used in Japan, the H5N1 flu strain is showing dramatic resistance to Roche's Tamiflu (oseltamivir) already on hand, so the government has been seeking GSK's Relenza (zanamivir), the main competitor, as an option. GSK KK said it would begin shipping the extra 2 million packs in April. (Click here for more